Track topics on Twitter Track topics that are important to you
GlaxoSmithKline will shut down its Shanghai neurological R&D operations in Zhangjiang Hi-Tech Park as part of a corporate reorganization that will focus the company's R&D work into several key areas: respiratory and HIV/infectious diseases, along with a lesser emphasis on oncology and immuno-inflammation. The overall restructuring, which will jettison some 30 current GSK projects, was announced by new GSK CEO Emma Walmsley, who has spent time working in Shanghai as Head of GSK's China Consumer Products division. GSK's Beijing-based vaccine R&D operations are not affected by the cuts. Despite the changes, GSK told Fierce Pharma it will expand in China to "accelerate the development of new medicines." More details....
Stock Symbol: (NYSE: GSK)
Share this with colleagues:
Original Article: GSK To Close Shanghai Neurological R&D OperationsNEXT ARTICLE
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...